Flexible use of copula-type model for dose-finding in drug combination clinical trials.

ABSTRACT: Identification of the maximum tolerated dose combination (MTDC) of cancer drugs is an important objective in phase I oncology trials. Numerous dose-finding designs for drug combination have been proposed over the years. Copula-type models exhibit distinctive advantages in this task over other models used in existing competitive designs. For example, their application enables the consideration of dose-limiting toxicities attributable to one of two agents. However, if a particular combination therapy demonstrates extremely synergistic toxicity, copula-type models are liable to induce biases in toxicity probability estimators due to the associated Fréchet-Hoeffding bounds. Consequently, the dose-finding performance may be worse than those of other competitive designs. The objective of this st

SUBMITTER: Hashizume K 

PROVIDER: S-EPMC10393268 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature